Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2036-06-08 | Direct | 8,150 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 8,150 · Balance 8,150 F1: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 23:43 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,150 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001437749-26-020213 · rdgdoc.xml · derivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,150 Underlying: Common Stock · 8,150 shares Expires 2036-06-08 F1 · derivative.exercise_date: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:01 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001437749-25-021270 · rdgdoc.xml · derivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires 2035-06-23 F1 · derivative.exercise_date: On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:22 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001437749-24-020411 · rdgdoc.xml · derivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2034-06-14 F1 · derivative.exercise_date: On June 14, 2024, in connection with the Reporting Person's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 5,750 shares of the Issuer's common stock under the Issuer's 2015 Equity Incentive Plan, as amended, in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:52 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 6,450 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001437749-23-026072 · rdgdoc.xml · derivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,450 Underlying: Common Stock · 6,450 shares Expires 2033-09-15 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing September 30, 2023. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 20:31 UTC | CervoMed Inc. CRVO · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 122 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-025311 · rdgdoc.xml · derivative · entry 3 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested. F1 · derivative.exercise_date: On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested. F1 · derivative.expiration_date: On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 20:31 UTC | CervoMed Inc. CRVO · Entity 7338 | Disposition to issuerCommon Stock | 45 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-025311 · rdgdoc.xml · nonDerivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 898 F1 · kind: On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested. F1 · price: On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 20:31 UTC | CervoMed Inc. CRVO · Entity 7338 | Exercise / conversionCommon Stock | 122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-025311 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:00 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-016502 · rdgdoc.xml · derivative · entry 3 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $263.84 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.88. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On May 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $263.84 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.88. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On May 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $263.84 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.88. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:00 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 68 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-016502 · rdgdoc.xml · nonDerivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,231 F1 · kind: On May 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $263.84 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.88. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On May 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $263.84 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.88. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:00 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-016502 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $263.84 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.88. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 23:20 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-005435 · rdgdoc.xml · derivative · entry 3 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366 Underlying: Common Stock · 183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 28, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $391.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.75. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On February 28, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $391.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.75. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On February 28, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $391.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.75. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 23:20 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 68 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-005435 · rdgdoc.xml · nonDerivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116 F1 · kind: On February 28, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $391.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.75. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On February 28, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $391.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.75. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 23:20 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-005435 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 28, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $391.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.75. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| November 30, 2022 Filed Dec 3, 2022 00:09 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-028356 · rdgdoc.xml · derivative · entry 3 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549 Underlying: Common Stock · 183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 30, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $442.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.50. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On November 30, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $442.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.50. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On November 30, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $442.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.50. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| November 30, 2022 Filed Dec 3, 2022 00:09 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 68 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-028356 · rdgdoc.xml · nonDerivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,001 F1 · kind: On November 30, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $442.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.50. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On November 30, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $442.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.50. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| November 30, 2022 Filed Dec 3, 2022 00:09 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-028356 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 30, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $442.00 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.50. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 31, 2022 Filed Sep 3, 2022 01:06 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-021841 · rdgdoc.xml · derivative · entry 3 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732 Underlying: Common Stock · 183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On August 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $462.30 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On August 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $462.30 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On August 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $462.30 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 31, 2022 Filed Sep 3, 2022 01:06 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 67 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021841 · rdgdoc.xml · nonDerivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886 F1 · kind: On August 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $462.30 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On August 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $462.30 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 31, 2022 Filed Sep 3, 2022 01:06 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021841 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 115 Shares and (ii) $462.30 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:37 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-014181 · rdgdoc.xml · derivative · entry 3 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915 Underlying: Common Stock · 183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 116 Shares and (ii) $550.07 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On May 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 116 Shares and (ii) $550.07 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On May 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 116 Shares and (ii) $550.07 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:37 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 67 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014181 · rdgdoc.xml · nonDerivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 F1 · kind: On May 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 116 Shares and (ii) $550.07 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On May 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 116 Shares and (ii) $550.07 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:37 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014181 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 31, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 116 Shares and (ii) $550.07 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $8.21. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 01:42 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 83,300 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-21-016512 · rdgdoc.xml · derivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 83,300 shares Expires 2031-07-01 F1 · derivative.exercise_date: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:27 UTC | CervoMed Inc. DFFN · Entity 7338 | PurchaseCommon Stock | 32,786 | $0.61 | $19,999.46 |
DisclosureSEC source: 0001437749-21-012537 · rdgdoc.xml · nonDerivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,786 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple open-market transactions at prices ranging from $0.6097 to $0.6141, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares sold at each separate price within such range. Read SEC document |
| September 01, 2020 Filed Oct 2, 2020 00:29 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantRestricted Stock Unit · Derivative | 54,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-020635 · rdgdoc.xml · derivative · entry 2 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,900 Underlying: Common Stock · 54,900 shares Expires not disclosed F2 · derivative.exercise_price: 2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 3. The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) quarterly installments on the last calendar day of each quarter over an 18-month period beginning on March 1, 2022. F3 · derivative.expiration_date: 3. The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) quarterly installments on the last calendar day of each quarter over an 18-month period beginning on March 1, 2022. Read SEC document |
| September 01, 2020 Filed Oct 2, 2020 00:29 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 67,400 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001437749-20-020635 · rdgdoc.xml · derivative · entry 1 Hollingsworth Jane H · CIK 0001297141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2030-09-01 F1 · derivative.exercise_date: 1. The shares underlying the options will vest in 18 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over an 18-month period beginning September 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.